2025
Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride Initiation
Feuerstadt P, Lu M, Terasawa E, Terreri B, Du S, Pi S, Westermeyer B, Ayyagari R, Lembo A, Moshiree B, Boules M, Cash B. Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride Initiation. Gastro Hep Advances 2025, 4: 100664. PMID: 40491438, PMCID: PMC12148438, DOI: 10.1016/j.gastha.2025.100664.Peer-Reviewed Original ResearchChronic idiopathic constipationHealth care resource utilizationHealth care costsCare costsIdiopathic constipationEvaluate health care resource utilizationMedication useStudy periodMedical health care costsMedical costsProportion of patientsIBM MarketScan Commercial ClaimsEconomic burdenEconomic burden of patientsMarketScan Commercial ClaimsIncreased pharmacy costsAssessed 6 monthsBurden of patientsTreatment initiationPrucaloprideAll-CauseOutpatient visitsPrescription fillsPatientsDiagnosis codes
2024
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States.
Cash B, Lu M, Lembo A, Feuerstadt P, Nguyen L, Terasawa E, Ayyagari R, Du S, Pi S, Westermeyer B, Terreri B, Boules M, Moshiree B. A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States. Journal Of Managed Care & Specialty Pharmacy 2024, 30: 1136-1148. PMID: 39321115, PMCID: PMC11424913, DOI: 10.18553/jmcp.2024.30.10.1136.Peer-Reviewed Original ResearchConceptsChronic idiopathic constipationHazard ratioIdiopathic constipationTreatment of chronic idiopathic constipationHigher treatment persistencePrescription medicationsComparator medicationUS Food and Drug AdministrationProportion of patientsIBM MarketScan Commercial ClaimsObservational cohort studyFood and Drug AdministrationAdjusted hazard ratiosMarketScan Commercial ClaimsProportion of daysAssociated with lower oddsTreatment persistencePrucaloprideCohort studyOdds ratioPrescription fillsPrescription therapyDrug AdministrationCompare persistenceInclusion criteriaClinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States
Lembo A, Cash B, Lu M, Terasawa E, Terreri B, Du S, Ayyagari R, Feuerstadt P, Moshiree B, Westermeyer B, Pi S, Boules M. Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States. Clinical And Translational Gastroenterology 2024, 15: e00687. PMID: 38357940, PMCID: PMC11124638, DOI: 10.14309/ctg.0000000000000687.Peer-Reviewed Original ResearchConstipation-related symptomsChronic idiopathic constipationProportion of patientsComplications 6 monthsIdiopathic constipationRetrospective cohort analysisDecreased 6 monthsMedicare Supplemental databaseICD-10 procedurePatient ageTreatment initiationClinical outcomesPrucalopride treatmentCohort analysisComplicationsPrucaloprideObservational studyPatientsSupplemental databaseICD-10 Procedure Coding SystemCommercial ClaimsDiagnosis codesICD-10-CMSymptomsClinical ModificationEfficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age, body mass index, and renal function: a post hoc analysis of phase III and IV, randomized, placebo-controlled clinical studies
Lembo A, Staller K, Boules M, Feuerstadt P, Spalding W, Gabriel A, Youssef A, Xie Y, Terreri B, Cash B. Efficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age, body mass index, and renal function: a post hoc analysis of phase III and IV, randomized, placebo-controlled clinical studies. Therapeutic Advances In Gastroenterology 2024, 17: 17562848241299731. PMID: 39664231, PMCID: PMC11632959, DOI: 10.1177/17562848241299731.Peer-Reviewed Original ResearchChronic idiopathic constipationBody mass indexSafety of prucalopridePlacebo-treated patientsRenal functionRenal impairmentEfficacy endpointIdiopathic constipationMass indexClinical studiesTreatment-related adverse eventsPlacebo-controlled clinical studyRenal impairment subgroupsMild renal impairmentModerate renal impairmentNormal renal functionProportion of patientsPost Hoc AnalysisUnderweight/healthy weightAdverse eventsPrucaloprideIII and IVSafety dataPatientsTreating adults
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply